Alkermes plc has undergone a transformation, shifting from a drug delivery and formulation company to an innovative pharma company. The group recently completed the spin-out of its oncology business and narrowed its focus to diseases of the central nervous system.
“2023 was a year of getting the pieces into place,” CEO Richard Pops told In Vivo. In 2024, Alkermes will...